Boston Scientific snags renal denervation developer SoniVie for $540M
The acquisition sets up the company to potentially compete against Medtronic and Recor Medical—whose respective FDA-approved procedures received temporary reimbursements from Medicare at the top of this year.
The acquisition sets up the company to potentially compete against Medtronic and Recor Medical—whose respective FDA-approved procedures received temporary reimbursements from Medicare at the top of this year.
